Placeholder Banner

A Patient Advocate’s Perspective on Foreign Price Controls

February 7, 2020

In a new video, Cynthia Bens, patient advocate and Senior Vice President of Public Policy at the Personalized Medicine Coalition, shares her views on how adopting foreign price controls for prescription medicines will impact patients in the U.S.

 

“I wouldn’t say the President’s proposal for reference pricing is the right way to deal with drug pricing issues. We need to look at the problem holistically. …
 
“What’s really challenging, right now, is all of the estimates on what the president’s foreign reference pricing proposal really means for patients is that there’s going to be a reduction in research and development. …
 
“The harms of the foreign reference pricing proposal really outweigh the benefits that patients are going to see.” 


To learn more about the flaws of importing foreign price controls, visit bio.org/save-cures.


###
 

Discover More
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…
WASHINGTON - (September 5, 2024) –The Biotechnology Innovation Organization (BIO) will launch the fall season of the award-winning “I am BIO” podcast on September 10. Now entering its fifth year, the podcast explores the intersection of…
July 17, 2024 – BIO President and CEO John F. Crowley today released the following statement after the U.S. Food & Drug Administration (FDA) announced a plan to establish a Rare Disease Innovation Hub that will utilize new and collaborative…